Differences in outcome and toxicity between Asian and caucasian patients with lung cancer treated with systemic therapy

Future Oncology

Volumn 8, Issue 4, 2012, Pages 451-462

  Soo, Ross A ^a,b   Kawaguchi, Tomoya ^c   Loh, Marie ^a,b   Ou, Sai Hong I ^d   Shieh, Marie P ^d   Cho, Byoung Chul ^e   Mok, Tony S ^f   Soong, Richie ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Yonsei University College of Medicine   (South Korea)

^f CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Asian; caucasian; chemotherapy; ethnicity; lung cancer; NSCLC; targeted therapy

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CRIZOTINIB; ERLOTINIB; ETOPOSIDE; GEFITINIB; IRINOTECAN; NAVELBINE; PACLITAXEL; PLACEBO;

ANEMIA; ASIAN; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CAUCASIAN; CLINICAL TRIAL; DRUG SAFETY; DRUG TOLERABILITY; GENETIC DIFFERENCE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; NEUTROPENIA; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; SOCIOECONOMICS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; LUNG NEOPLASMS; TREATMENT OUTCOME;

EID: 84860183475     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.25     Document Type: Review

References (67)

1. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol. Biomarkers Prev. 19(8), 1893-1907 (2010).
2. Youlden DR, Cramb SM, Baade PD. The international epidemiology of lung cancer: geographical distribution and secular trends. J. Thorac. Oncol. 3(8), 819-831 (2008).
3. Alberg AJ, Brock MV, Samet JM. Epidemiology of lung cancer: looking to the future. J. Clin. Oncol. 23(14), 3175-3185 (2005). (Pubitemid 46217457)
4. Cetin K, Ettinger DS, Hei YJ, O'Malley CD. Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, Epidemiology and End Results Program. Clin. Epidemiol. 3, 139-148 (2011).
5. Ou SH, Ziogas A, Zell JA. Asian ethnicity is a favorable prognostic factor for overall survival in non-small cell lung cancer (NSCLC) and is independent of smoking status. J. Thorac. Oncol. 4(9), 1083-1093 (2009).
6. Ferguson MK, Skosey C, Hoffman PC et al. Sex-associated differences in presentation and survival in patients with lung cancer. J. Clin. Oncol. 8(8), 1402-1407 (1990). (Pubitemid 20252313)
7. Ferguson MK, Wang J, Hoffman PC et al. Sex-associated differences in survival of patients undergoing resection for lung cancer. Ann. Thorac. Surg. 69(1), 245-250 (2000). (Pubitemid 30078857)
8. Batevik R, Grong K, Segadal L et al. The female gender has a positive effect on survival independent of background life expectancy following surgical resection of primary non-small cell lung cancer: a study of absolute and relative survival over 15 years. Lung Cancer 47(2), 173-181 (2005). (Pubitemid 40082160)
9. Wisnivesky JP, Halm EA. Sex differences in lung cancer survival: do tumors behave differently in elderly women? J. Clin. Oncol. 25(13), 1705-1712 (2007). (Pubitemid 46797951)
10. Naito C. Necessity and requirements of bridging studies and their present status in Japan. Int. J. Clin. Pharmacol. Ther. 38(2), 80-86 (2000). (Pubitemid 30077983)
11. Sekine I, Yamamoto N, Nishio K, Saijo N. Emerging ethnic differences in lung cancer therapy. Br. J. Cancer 99(11), 1757-1762 (2008).
12. O'Donnell PH, Dolan ME. Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin. Cancer Res. 15(15), 4806-4814 (2009).
13. Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int. J. Cancer. 118(2), 257-262 (2006). (Pubitemid 41779062)
14. Haiman CA, Stram DO, Wilkens LR et al. Ethnic and racial differences in the smoking related risk of lung cancer. N. Engl. J. Med. 354(4), 333-342 (2006). (Pubitemid 43145058)
15. Brennan P, Hainaut P, Boffetta P. Genetics of lung-cancer susceptibility. Lancet Oncol. 12(4), 399-408 (2011).
16. Yokota J, Shiraishi K, Kohno T. Genetic basis for susceptibility to lung cancer: recent progress and future directions. Adv. Cancer Res. 109, 51-72 (2010).
17. Ou SH, Ziogas A, Zell JA. Prognostic factors for survival in extensive stage small cell lung cancer (ED-SCLC): the importance of smoking history, socioeconomic and marital statuses, and ethnicity. J. Thorac. Oncol. 4(1), 37-43 (2009).
18. Lara PN Jr, Chansky K, Shibata T et al. Common arm comparative outcomes analysis of Phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: fnal patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124. Cancer 116(24), 5710-5715 (2010).
19. Ou SH, Zell JA, Ziogas A, Anton-Culver H. Prognostic factors for survival of stage I non small cell lung cancer patients: a population-based analysis of 19,702 stage I patients in the California Cancer Registry from 1989 to 2003. Cancer 110(7), 1532-1541 (2007). (Pubitemid 47463068)
20. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers-a different disease. Nat. Rev. Cancer 7(10), 778-790 (2007). (Pubitemid 47463669)
21. Ahn MJ, Lee J, Park YH et al. Korean ethnicity as compared with white ethnicity is an independent favorable prognostic factor for overall survival in non-small cell lung cancer before and after the oral epidermal growth factor receptor tyrosine kinase inhibitor era. J. Thorac. Oncol. 5(8), 1185-1196 (2010).
22. Kawaguchi T, Matsumura A, Fukai S et al. Japanese ethnicity compared with Caucasian ethnicity and never-smoking status are independent favorable prognostic factors for overall survival in non-small cell lung cancer: a collaborative epidemiologic study of the National Hospital Organization Study Group for Lung Cancer (NHSGLC) in Japan and a southern California Regional Cancer Registry databases. J. Thorac. Oncol. 5(7), 1001-1010 (2010).
23. Berz D, Faricy-Anderson KE, Weitzen S, Birnbaum A, Strauss G. Do race and ethnicity predict survival in metastatic non-small cell lung cancer? Med. Health RI 93(10), 299-302 (2010).
24. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized Phase II trial of geftinib for previously treated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 21(12), 2237-2246 (2003). (Pubitemid 46621858)
25. Shigematsu H, Lin L, Takahashi T et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl Cancer Inst. 97(5), 339-346 (2005). (Pubitemid 40425952)
26. Nishiwaki Y, Yano S, Tamura T et al. Subset analysis of data in the Japanese patients with NSCLC from IDEAL 1 study on geftinib. Gan To Kagaku Ryoho. 31(4), 567-573 (2004).
27. Shepherd F, Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353(2), 123-132 (2005). (Pubitemid 41058344)
28. Thatcher N, Chang A, Parikh P et al. Geftinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366(9496), 1527-1537 (2005). (Pubitemid 41540110)
29. Slebos RJ, Hruban RH, Dalesio O, Mooi WJ, Offerhaus GJ, Rodenhuis S. Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. J. Natl Cancer Inst. 83(14), 1024-1027 (1991).
30. Ahrendt SA, Decker PA, Alawi EA et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 92(6), 1525-1530 (2001). (Pubitemid 32947838)
31. Noda N, Matsuzoe D, Konno T, Kawahara K, Yamashita Y, Shirakusa T. K-ras gene mutations in non-small cell lung cancer in Japanese. Oncol. Rep. 8(4), 889-892 (2001). (Pubitemid 33758143)
32. Wu CC, Hsu HY, Liu HP et al. Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications. Cancer 113(11), 3199-3208 (2008).
33. Mao C, Qiu LX, Liao RY et al. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies. Lung Cancer 69(3), 272-278 (2010).
34. Linardou H, Dahabreh IJ, Kanaloupiti D et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 9(10), 962-972 (2008).
35. Solomon B, Varella-Garcia M, Camidge DR. ALK gene rearrangements: a new therapeutic target in a molecularly defned subset of non-small cell lung cancer. J. Thorac. Oncol. 4(12), 1450-1454 (2009).
36. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363(18), 1693-1703 (2010).
37. Ou SHI, Salgia R, Clark J et al. Comparison of Crizotinib (PF-02341066) pharmacokinetics between Asian and non-Asian patients with advanced malignancies. Presented at: 4th Asia Pacifc Lung Cancer Conference. Seoul, Korea, 10-14 November, 2010 (Abstract O35).
38. Sekine I, Nokihara H, Yamamoto N et al. Common arm analysis: one approach to develop the basis for global standardization in clinical trials of non-small cell lung cancer. Lung Cancer 53(2), 157-164 (2006). (Pubitemid 43994238)
39. Gandara DR, Kawaguchi T, Crowley J et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J. Clin. Oncol. 27(21), 3540-3546 (2009).
40. Reck M, von Pawel J, Zatloukal P et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J. Clin. Oncol. 27(8), 1227-1234 (2009).
41. Mok TS, Hsia TC, Tsai CM et al. Effcacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy: a substudy of the Avastin in Lung trial. Asia Pac. J. Clin. Oncol. 7(Suppl. 2), 4-12 (2011).
42. Pirker R, Pereira JR, Szczesna A et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FILEX): an open-label randomized Phase III trial. Lancet 373(9674), 1525-1531 (2009).
43. Soo RA, Loh M, Mok TS et al. Ethnic differences in survival outcome in patients with advanced stage non-small cell lung cancer: results of a meta-analysis of randomized controlled trials. J. Thorac. Oncol. 6(6), 1030-1038 (2011).
44. Hasegawa Y, Kawaguchi T, Kubo A et al. Ethnic difference in hematological toxicity in patients with non-small cell lung cancer treated with chemotherapy. A pooled analysis on Asian versus non-Asian in Phase II and III clinical trials. J. Thorac. Oncol. 6(11), 1881-1888 (2011).
45. Moodie PF, Nelson NA, Koch GG. A non-parametric procedure for evaluating treatment effect in the meta-analysis of survival data. Stat. Med. 23(7), 1075-1093 (2004). (Pubitemid 38477068)
46. Millward MJ, Boyer MJ, Lehnert M et al. Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a Phase II study in Caucasian and Asian patients. Ann. Oncol. 14(3), 449-454 (2003). (Pubitemid 36367424)
47. Yap TA, Olmos D, Brunetto AT et al. Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J. Clin. Oncol. 29(10), 1271-1279 (2011).
48. Desta Z, Zhao X, Shin JG et al. Clinical signifcance of the cytochrome P450 2C19 genetic polymorphism. Clin. Pharmacokinet. 41(12), 913-958 (2002). (Pubitemid 35168437)
49. Nishina T, Hirashima T, Sugio K et al. The effect of CYP2C19 polymorphism on the tolerability of ARQ 197: results from Phase I trial in Japanese patients with metastatic solid tumors. J. Clin. Oncol. 29(Suppl.) Abstract 2516 (2011).
50. Schwartsmann G, Ratain MJ, Cragg GM et al. Anticancer drug discovery and development throughout the world. J. Clin. Oncol. 20(18 Suppl.), S47-S59 (2002).
51. Takano T, Fukui T, Ohe Y et al. EGFR mutations predict survival beneft from geftinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after geftinib approval in Japan. J. Clin. Oncol. 26(34), 5589-5595 (2008).
52. Mok TS, Wu YL, Thongprasert S et al. Geftinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361(10), 947-957 (2009).
53. Yang CH, Fukuoka M, Mok TS et al. Final overall survival (OS) results from a Phase III, randomized, open-label, first-line study of geftinib (G) v carboplatin/paclitaxel (C/P) in clinically selected patients with advanced non small cell lung cancer (NSCLC) in Asia (IPASS). Ann. Oncol. 21(Suppl. 8), viii1-viii12 (2010).
54. Wu M, Zhao J, Song SW et al. EGFR mutations are associated with prognosis but not with the response to front-line chemotherapy in the Chinese patients with advanced non-small cell lung cancer. Lung Cancer 67(3), 343-347 (2010).
55. Gandara DR, Grimminger PP, Mack PC, Danenberg PV, Lara P, Danenberg KD. Histology-and gender-related associations of ERCC1, RRM1, and TS biomarkers in 1,802 patients with NSCLC: implications for therapy. J. Clin. Oncol. 28(Suppl. 15) Abstract 7513 (2010).
56. Nomura M, Shigematsu H, Li L et al. Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. PLoS Med. 4(4), E125 (2007).
57. Colombo F, Falvella FS, Galvan A et al. A 5'-region polymorphism modulates promoter activity of the tumor suppressor gene MFSD2A. Lung Cancer. 55(3), 271-277 (2007).
58. Spinola M, Falvella FS, Galvan A et al. Ethnic differences in frequencies of gene polymorphisms in the MYCL1 region and modulation of lung cancer patients' survival. Lung Cancer 55(3), 271-277 (2007). (Pubitemid 46329186)
59. Janssen-Heijnen ML, Gatta G, Forman D, Capocaccia R, Coebergh JW. Variation in survival of patients with lung cancer in Europe, 1985-1989. EUROCARE Working Group. Eur. J. Cancer. 34(14), 2191-2196 (1998). (Pubitemid 29036885)
60. Soo RA, Anderson BO, Cho BC et al. First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol. 10(11), 1102-1110 (2009).
61. Albain KS, Unger JM, Crowley JJ, Coltman CA Jr, Hershman DL. Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. J. Natl Cancer Inst. 101(14), 984-992 (2009).
62. Mackillop WJ, Zhang-Salomons J, Paszat L, Holowaty E. Socioeconomic status and cancer survival in Ontario. J. Clin. Oncol. 15(4), 1680-1689 (1997). (Pubitemid 27167409)
63. Mulligan CR, Meram AD, Proctor CD, Wu H, Zhu K, Marrogi AJ. Unlimited access to care: effect on racial disparity and prognostic factors in lung cancer. Cancer Epidemiol. Biomarkers Prev. 15(1), 25-31 (2006).
64. Bryant AS, Cerfolio RJ. Impact of race on outcomes of patients with non-small cell lung cancer. J. Thorac. Oncol. 3(7), 711-715 (2008).
65. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 12(2), 175-180 (2011).
66. Li C, Fang R, Sun Y et al. Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. PLoS ONE 6(11), E28204 (2011).
67. Kris MG, Johnson BE, Kwiatkowski DJ et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: the NCI's Lung Cancer Mutation Consortium (LCMC). J. Clin. Oncol. 29(Suppl.), Abstract CRA7506 (2011).